Utah Medical Products (UTMD)
(Delayed Data from NSDQ)
$68.00 USD
+0.78 (1.16%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $67.56 -0.44 (-0.65%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Utah Medical Products, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 50 | 52 | 49 | 42 | 47 |
Cost Of Goods | 20 | 20 | 18 | 17 | 17 |
Gross Profit | 30 | 32 | 31 | 26 | 29 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 12 | 12 | 12 | 12 |
Income After Depreciation & Amortization | 17 | 20 | 19 | 14 | 18 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 20 | 21 | 19 | 14 | 18 |
Income Taxes | 3 | 4 | 4 | 3 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 17 | 16 | 15 | 11 | 15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 17 | 16 | 15 | 11 | 15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 23 | 27 | 26 | 21 | 25 |
Depreciation & Amortization (Cash Flow) | 6 | 7 | 7 | 7 | 7 |
Income After Depreciation & Amortization | 17 | 20 | 19 | 14 | 18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.64 | 3.64 | 3.66 | 3.67 | 3.74 |
Diluted EPS Before Non-Recurring Items | 4.57 | 4.52 | 4.15 | 3.00 | 3.78 |
Diluted Net EPS (GAAP) | 4.57 | 4.52 | 4.04 | 2.94 | 3.94 |
Fiscal Year end for Utah Medical Products, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 10.40 | 11.34 | 12.33 | 12.51 | 12.87 |
Cost Of Goods | 4.15 | 4.57 | 5.24 | 5.15 | 5.13 |
Gross Profit | 6.25 | 6.77 | 7.10 | 7.36 | 7.74 |
SG&A, R&D, and Dept/Amort Expenses | 2.82 | 2.89 | 3.16 | 3.39 | 3.31 |
Income After SG&A, R&D, and Dept/Amort Expenses | 3.43 | 3.88 | 3.94 | 3.97 | 4.43 |
Non-Operating Income | 0.77 | 0.92 | -1.96 | 0.81 | 0.75 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 4.21 | 4.80 | 5.02 | 4.78 | 5.17 |
Income Taxes | 0.76 | 0.84 | 0.73 | 0.85 | 0.97 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 3.45 | 3.96 | 4.29 | 3.94 | 4.20 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 3.45 | 3.96 | 4.29 | 3.94 | 4.20 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.53 | 3.62 | 3.63 | 3.64 | 3.64 |
Diluted EPS Before Non-Recurring Items | 0.98 | 1.09 | 1.18 | 1.08 | 1.15 |
Diluted Net EPS (GAAP) | 0.98 | 1.09 | 1.18 | 1.08 | 1.15 |